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PREDICTING RISK OF MALIGNANCY IN PATIENTS WITH 
INDETERMINATE THYROID NODULES 
NICHOLAS CARNES 
ABSTRACT 
Thyroid cancer is the most prevalent endocrine cancer (1). The prevalence of 
palpable thyroid nodules in the general adult population is 4% to 7% (2). Ultrasound 
imaging detects thyroid nodules in 19%-68% of randomly selected individuals (3). The 
rate of thyroid cancer in nodules found on US is 4% to 15% (4). In order to evaluate 
thyroid nodules patients undergo thyroid ultrasonography and, if needed, a fine-needle 
aspiration biopsy. Of all fine-needle aspiration biopsies, 15-30% are indeterminate on 
cytology (5). While only 3% of these nodules are malignant on average, a much higher 
percentage of nodules are surgically removed in order to rule out malignancy after 
indeterminate FNA results. Our goal is to identify clinical and ultrasound predictors of 
benign results in indeterminate nodules, to assist physicians in selecting nodules for 
surgical removal versus monitoring with ultrasound imaging.  
Between October 2010 and November 2017 there were 129 patients with 134 
thyroid nodules from Temple University Hospital, Jeanes Hospital, and Fox Chase 
Cancer Center who had a total or partial thyroidectomy after a cytology report of at least 
one AUS or FLUS thyroid nodule. These patients were evaluated for age, sex, BMI, 
TSH, fT4, tT3, nodule size, and ultrasonography features to determine if any features 
were predictive of a benign or malignant thyroid nodule. 
 v 
Additionally, we looked at whether any of these features were more likely to 
occur in an AUS nodule or a FLUS nodule. We found that none of the demographic 
factors, thyroid function tests, or ultrasound features were good predictors of malignancy 
in AUS or FLUS thyroid nodules. We found that AUS nodules are more likely to be 
malignant than FLUS nodules, and this held true when we accounted for age, sex, 
smoking history, and BMI. We concluded that demographic factors and thyroid function 
tests are unable to predict increased risk of malignancy in Bethesda category III nodules, 
AUS nodules are more likely to be malignant that FLUS nodules, and nodules with at 
least one suspicious ultrasound feature are more likely to be AUS nodules than FLUS 
nodules due to AUS nodules having nuclear atypia and FLUS nodules having 
architectural atypia.  
 vi 
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INTRODUCTION 
Thyroid cancer is the most prevalent type of endocrine cancer (1). Differentiated 
thyroid cancers account for greater than 90% of all thyroid cancers. Papillary thyroid 
cancer is the most common, and primary lymph node metastases occur between 30% and 
40% of cases (6). The prevalence of palpable thyroid nodules in the general adult 
population is 4% to 7% (2). Ultrasound (US) can detect thyroid nodules in 19%-68% of 
randomly selected individuals, and thyroid cancer can occur in 4-15% of nodules (3, 4). 
When a nodule is discovered on clinical exam or other imaging study such as CT or MRI 
a thyroid US is required for assessment. A patient may undergo a fine-needle aspiration 
biopsy based on level of suspicion of nodule on US.   
 Fine needle aspiration cytology was first introduced in Scandinavia in the 1950’s 
and gained popularity in the 1980s (7). In 2010, the National Cancer Institute published 
the Bethesda System for Reporting Thyroid Cytopathology to establish uniform 
terminology for the evaluation of thyroid nodules that undergo FNA (8, 9). This system 
comprises of 6 categories ranging from non-diagnostic (I) to malignant (VI). There are 
three categories of indeterminate findings. Category III contains diagnoses of atypia of 
undetermined significance or follicular lesion of undetermined significance. Category IV 
contains diagnoses of suspicious for follicular neoplasm or follicular neoplasm. Category 
V contains diagnoses of suspicious for papillary carcinoma. According to the American 
Thyroid Association category III has a malignancy rate between 5 and 15%, category IV 
has a malignancy rate of 15-30% and category V has a malignancy rate of 60-75% (10). 
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 The histologic findings of a FNA determine which category in the Bethesda scale 
it will be assigned. Clinicians are advised to limit diagnosing samples as category III  
because AUS and FLUS nodules are generally due to sample preparation artifact and 
architectural or nuclear atypia that are not readily assigned to other categories (11–13). 
One of the problems with the Bethesda system is the large amount of intra and 
interpersonal variability due to a lack of strict criteria for sample. This why there is a 
large variability in the number of total AUS/FLUS diagnosis between hospitals. Different 
systems have found the rate of AUS/FLUS nodules to occur between 1 and 27% of all 
FNA results, and their malignancy rates range from 6% to 41% (14). 
 There are several different proposed methods to guide physicians in 
recommending FNA based on ultrasound features. According to the ATA guidelines, 
certain features of US have been found to be more predictive of a malignant nodule. 
There are 5 categories on which features are described: shape, echogenicity, echogenic 
foci, margin, and composition. Shape, height, and width of a nodule is evaluated on the 
axial plane (11). Shape can be either taller than wide or wider than tall. Echogenicity 
describes the reflectivity of the thyroid nodule to reflect sound waves, and is compared to 
surrounding thyroid tissue. Echogenicity can be anechoic, hyperechoic or isoechoic, 
hypoechoic, or very hypoechoic. Locations in a thyroid nodule that contains 
mineralization show up as echogenic foci, and can be either none or large with comet-tall 
artifacts, macrocalcifications, peripheral calcifications, or punctate echogenic foci. 
Margins describe the nodule in relation to surrounding healthy tissue. Margins can be 
described as smooth, ill-defined, lobulated or irregular, or extra-thyroidal extension. 
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Composition describes whether the nodule is made up of cystic spaces or solid spaces. 
Composition can be cystic, spongiform, mixed solid and cystic, or solid. Under the ATA 
guidelines a nodule can be graded as benign, very low suspicion, low suspicion, 
intermediate suspicion, or high suspicion for malignancy. High suspicion nodules are 
solid, hypoechoic nodules or solid hypoechoic nodules with a partial cystic component 
with at least one of the following features: irregular margins, microcalcifications, taller 
than wide shape, or extrathyroidal extensions. Intermediate suspicion nodules are 
hypoechoic, solid nodules with smooth margins that do not have microcalcifications, 
extrathyroidal extension, or taller than wide shape. Low suspicion nodules are isoechoic 
or hyperechoic solid nodules, or partially cystic nodules without microcalcification, 
irregular margin, taller than wide shape, or extrathyroidal extension. Very low suspicion 
nodules are spongiform or partially cystic without any sonographic features described in 
the low, intermediate, or high suspicion grades. Benign nodules are purely cystic with no 
solid component. Malignancy rates of nodules with different ultrasound characteristics 
are shown in Figure 1. 
The ACR TI-RADS system that was modeled after the ACR BI-RADS, a widely 
accepted breast imaging model, has been used to predict malignancy from thyroid 
ultrasounds. The ACR TI-RADS uses a point based system to determine whether a 
nodule is benign, not suspicious, mildly suspicious, moderately suspicious, or highly 
suspicious, as shown in Figure 2. FNA is recommended based on nodule size after a 
nodule is given at least 3 points. Features that are more likely to be malignant include 
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microcalcifications, hypoechogenicity, taller-than-wide shape, irregular margins, and 
extrathyroidal extension (11, 15).  
A relatively new approach to thyroid nodule diagnoses is genetic sequencing. 
There are three main molecular panels that are available: Afirma, ThyroSeq v2.1, and 
ThyGenX/ThyraMIR (16). The Afirma Gene Expression Classifier is a genetic test 
developed by Veracyte Inc that analyzes 167 different genes to determine whether a 
sample is benign or suspicious of malignancy (17, 18). Of the 167 genes, 142 are used to 
rule out the majority of carcinomas, and the other 25 genes rule out rare neoplasms (19). 
Afirma is very good at ruling out malignancy in indeterminate nodules with a negative 
predictive value (NPV) of 95%, but is very poor at diagnosing carcinoma with a positive 
predictive value (PPV) near 38% (20, 21). Another problem with Afirma is its cost 
effectiveness. The Afirma GEC is an expensive test that can only be used to rule out 
malignancy. The Afirma GEC has been shown to be both more costly and less accurate 
for evaluating indeterminate cytology thyroid nodules than a partial lobectomy (22). 
When used for indeterminate nodules that have a low risk of malignancy it can prevent 
unnecessary surgery. ThyroSeq is a genetic test out of the University of Pittsburgh 
Medical Center that sequences for detection in over a thousand places of 14 cancer 
related genes and for 42 types of gene fusions (13). The 14 genes the sequencing can 
provide detailed information on the specific genes includes AKT1, BRAF, CTTNB1, 
GNAS, HRAS, KRAS, NRAS, PIK3CA, PTEN, RET, TP53, TSHR, TERT, and 
EIF1AX. ThyroSeq has a higher PPV than Afirma at 77% (7), but still has a high NPV at 
97% (13). The ThyGenX and ThyraMIR tests are a 7 gene mutational panel and a  
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gene expression classifier involving 10 microRNAs. The ThyGenX/ThyraMIR test has a 
NPV of 94% and PPV of 74% (24). The ThyraMIR test is usually performed if the 
ThyGenX mutational panel comes back negative. 
Another genetic marker that is commonly tested is the BRAF gene. A BRAF 
mutation is the main genetic event in PTC, making it a good predictor of malignancy. 
BRAF is involved in the activation of the MAP/ERK/MEK signaling pathway, which 
activates cell growth and proliferation. BRAF expression is restricted in most tissues, but 
is upregulated in many cancer cells. BRAF modulates the expression of genes that 
modify PTC features including fibronectin, vimentin, and prohibitin (25). Kondo et al. 
(2007) found that the BRAF gene is upregulated in 94% of 47 well-differentiated thyroid 
neoplasms (26). The most common mutation in the BRAF gene causes a V600E shift 
from valine to glutamic acid, and more than 90% of the known BRAF mutations cause 
this shift (27). 
Multiple studies have investigated the association between obesity and thyroid 
cancers. Obesity is associated with insulin resistance which can result in type II diabetes 
mellitus. Insulin resistance may also be associated with thyroid abnormalities (28, 29). 
One possible mechanism for obesity related thyroid abnormalities is through insulin-like 
growth factor 1. Insulin resistance through obesity causes upregulation of insulin which 
in turn decreases IGF-1-binding proteins and increases IGF-1 levels (28). IGF-1 receptors 
are upregulated in most cancer cells, causing increased cancer risk for obese individuals.  
The increased number of adipocytes in obese subjects cause multiple problems 
that may impact carcinomas. Adipocytes release adiponectin, a protein involved in 
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glucose regulation and the breakdown of fatty acids. Additionally, it has anti-
inflammatory and insulin sensitizing effects. Obese subjects have decreased amounts of 
adiponectin, increasing inflammation and insulin resistance which are known risk factors 
for carcinogenesis (30). Leptin, a hormone secreted by adipocytes is also suspected of 
affecting the thyroid through upregulation of thyrotropin-releasing hormone (28). 
According to the ATA about 7% of all thyroid biopsies are read as AUS/FLUS, 
and the malignancy risk of an AUS/FLUS nodule is between 5-15%. The current study 
aims to look at demographic and US features to determine if there are any predictive 
factors of malignancy in nodules diagnosed as AUS/FLUS.  
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Figure 2. Chart of the five categories of the ACR TI-RADS system with follow-up 
criteria and explanatory notes. Figure taken from Tessler et al. (2017)(11). 
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METHODS  
 
 Patients who were seen for evaluation of thyroid nodules between November 
2010 and October 2017 were selected from the Temple University Hospital, Jeanes 
Hospital, and Temple Fox Chase Cancer Center Endocrinology clinics or ENT clinics. A 
retrospective electronic chart review was performed. All patients’ charts with a diagnosis 
of thyroid cancer, thyroid nodule, multiple thyroid nodules, goiter, uni or multinodular 
goiter (toxic or nontoxic) seen at the above sites were included. Patients were excluded if 
they did not have a follow up FNA cytology and surgical pathology. For the present 
analysis patients who had FNA cytology results of Bethesda class III, atypia of 
undetermined significance or follicular lesion of undetermined significance were 
included.  
A list of 1036 patients who received either a total and partial thyroidectomy was 
obtained through Epic EMR from Temple University Hospital, Jeanes Hospital, and 
Temple Fox Chase Cancer Center. Of those 1036 patients, 129 were found to have a total 
or partial thyroidectomy and at least 1 FNA cytology report of Bethesda class III nodule. 
One hundred thirty four thyroid nodules were included in the study. 
Demographic data analysis included, sex, age, ethnicity, smoking status, height, 
weight, BMI, thyroid function tests, thyroid ultrasound results, FNA cytology results, and 
thyroid surgical pathology results. Ethnicity categories were Caucasian, African 
American, Hispanic, and other. Smoking status categories were never smoker, current 
smoker, or former smoker. Thyroid function tests included TSH, free T4, and total T3. 
Thyroid nodule FNA results were either AUS or FLUS categories.  
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We selected US images from the most recent US before the patient’s partial or 
total thyroidectomy. Investigators performed an independent review of US images. 
Investigators were blinded to final diagnosis of nodule and radiology report. The 
investigator performing the review was an endocrinologist with training and experience 
in performing thyroid US and FNA. US images were reviewed for shape, margins, 
echogenicity, texture, presence of a halo, calcification, calcification pattern, and Doppler. 
Shape was defined as either oval, round or taller than wide. Margins were either regular 
or irregular and well-defined or ill-defined. Echogenicity was defined as hyperechoic, 
isoechoic, hypoechoic, mixed hyperechoic to hypoechoic, or mixed isoechoic to 
hypoechoic. Texture was defined as either solid, cystic or mixed solid and cystic. If there 
were calcifications, they were defined as interrupted rim, annular-like or crescent-like 
peripheral, or intranodular coarse. Doppler was defined as peripheral vascularity, central 
vascularity, or both. Halo was defined as yes, no, or partial halo.  
Surgical pathology results confirmed whether each individual nodule was benign 
or malignant. If the nodule in question was not reported as a malignant carcinoma on 
surgical pathology it was classified benign. If any incidental microcarcinomas not located 
in the specific Bethesda III nodule were identified, the nodule was still considered 
benign.  
  Independent two-sample t-tests were performed to determine whether age, height, 
weight, BMI, TSH, and fT4 levels were risk factors for malignancy. Chi-squared tests 
were used to determine the malignancy risk of all ultrasonography features, sex, 
ethnicity, and smoking history. Chi-squared tests were also used to determine if 
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ultrasonography features were predictive of an AUS or FLUS nodule. All statistical tests 
were performed with The SAS institute’s JMP 13 software.  
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RESULTS 
 
 Of the 134 thyroid nodules from 129 patients, 53 were diagnosed as AUS and 81 
were diagnosed as FLUS. The AUS nodules had a malignancy rate of 33% and FLUS 
nodules had a malignancy rate of 17%. There was a significant difference between 
malignancy rates of AUS and FLUS nodules (p=0.027). Furthermore, when accounting 
for age, sex, smoking history, and BMI, nodules diagnosed AUS were still significantly 
more likely to be malignant than FLUS nodules (p=0.034).There was no association 
between malignancy and age (p=0.96), height (p=0.36), weight (p=0.58), BMI (p=0.5), 
TSH (p=0.55), FT4(p=0.75), nodule size(p=0.68), sex (p=0.17), smoking history 
(p=0.44) or ethnicity (p=0.52). Average age for benign and malignant nodules was 55.3 ± 
14 and 55.4 ± 15 respectively. Average BMI for benign and malignant nodules was 29.6 
± 5.9 and 30.5 ± 6.3. There were a total of 90 females and 39 males in this study sample. 
Average TSH levels in benign and malignant nodules were 1.69 ± 1.24 and 1.57 ± 0.72 
while the free T4 levels were 1.19 ± 0.93 and 1.27 ± 0.75. Distribution of demographic 
information and thyroid function tests are shown in Table 1 and Table 2. While total T3 
was looked at, less than 10% of the study sample had records of total T3, so statistical 
analysis was deferred. There was no significant difference between malignancy and the 
individual ultrasound features of shape, margins (p=0.92, 0.91), echogenicity (p= 0.55), 
texture (p=0.175), or halo (p=0.87). There were an insufficient number of calcified 
nodules (n=6) and nodules with extrathyroidal extension (n=0) to warrant statistical tests. 
All nodules except one had a shape of oval, and only three nodules were not categorized 
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Table 1. Comparison of age, BMI, nodule size and thyroid function tests between 
benign and malignant nodules. 
 Mean  total (SD) Mean benign Mean Malignant p-value 
Age (years) 55.3 (14.1) 55.3 (14.0) 55.4 (15.0) 0.96 
Weight (kg) 84.4 (19.6) 84.0 (20.1) 86.1 (18.5) 0.58 
Height (m) 1.68 (0.09) 1.67 (0.10) 1.69 (0.08) 0.36 
BMI 29.8 (6.0) 29.6 (5.9) 30.5 (6.3) 0.50 
TSH uIU/ml 1.66 (1.13) 1.69 (1.24) 1.57 (0.72) 0.55 
fT4 (ng/dl) 1.21 (0.89) 1.19 (0.93) 1.27 (0.75) 0.75 
tT3 (ng/dl) 112 (32.5) 111 (34) 121*  
Nodule Size(cm) 2.72 (1.28) 2.69 (1.21) 2.8 (1.45) 0.68 
*Only 1 malignant nodule was measured for tT3 
 
by margin as regular. Therefore, we excluded shape and regular or irregular margins from 
statistical analysis. 
We investigated whether certain US features were more common in the AUS and 
FLUS subcategories. We found no significant difference between the AUS and FLUS 
categories with regards to shape, margins (p=0.99), echogenicity (p=0.168), texture 
(p=0.69), halo (p=0.22), or Doppler (p=0.42). The distribution of US features is shown in 
Table 3. We also explored whether different demographics were more likely to result in 
an AUS of FLUS nodule. No significant differences were noted between the AUS and 
FLUS subcategories and age (p=0.58), sex (p=0.64), BMI (p=0.62), TSH (p=0.29), free 
T4 (p=0.98), nodule size (p=0.86), or smoking history (p=0.61). There was a significant 
difference for height (p=0.0435) and ethnicity (0.047). Demographic and thyroid function 
tests with regards to AUS and FLUS nodules is shown in Table 2 and Table 4. Taller 
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patients were more likely to have FLUS nodules and patients of Hispanic descent were 
more likely to have AUS nodules than FLUS. However, for height there was one 
individual with an AUS nodule that was 0.2 meters shorter than the nearest individual, 
and when that individual was excluded from the group there was no significant difference 
between the two groups (p=0.149). Additionally, we found that males are more likely 
than females to have malignant AUS nodules, but there was no significant difference for 
FLUS nodules (p=0.013). 
 We tested whether having at least 1 characteristic that is likely to cause 
malignancy increases risk for malignancy. We classified malignant traits as ill-defined, 
irregular, hypoechoic, solid, or had calcification. We found a trend that a nodule with at 
least 1 suspicious characteristic was more likely to be malignant (p=0.127). However, we 
did find that nodules with at least 1 suspicious characteristic was more likely to be an 
AUS nodule than a FLUS nodules (p=0.032).  
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Table 2. Comparison of demographic features between benign, malignant, AUS and 
FLUS nodules. 
 Total AUS FLUS Benign Malignant 
Sex 
      Male 
      Female 
      p-value 
 
41(31%) 
93 (69%) 
 
15 (28%) 
38 (72%) 
 
26 (32%) 
55 (68%) 
0.64 
 
28 (28%) 
74 (72%) 
 
13 (41%) 
19 (59%) 
0.165 
Smoking History 
      Never 
      Former 
      Current 
      p-value 
 
81 (61%) 
33 (25%) 
19 (14% 
 
34 (64%) 
11 (21%) 
8 (15%) 
 
 
47 (58%) 
22 (28%) 
11 (14%) 
0.61 
 
59 (58%) 
27 (27%) 
15 (15%) 
 
22 (69%) 
6 (19%) 
4 (12%) 
0.63 
Ethnicity 
      African American 
      Caucasian 
      Hispanic 
      Other 
     p-value 
 
30 (22%) 
75 (56%) 
22 (17%) 
7 (5%) 
 
13 (25%) 
23 (43%) 
14 (26%) 
3 (6%) 
 
17 (21%) 
52 (64%) 
8 (10%) 
4 (5%) 
0.047 
 
25 (24%) 
56 (55%) 
17 (17%) 
4 (4%) 
 
5 (16%) 
19 (59%) 
5 (16%) 
3 (9%) 
0.52 
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Table 3. Distribution of ultrasound features between benign, malignant, AUS and 
FLUS nodules. 
US feature Total AUS FLUS Benign Malignant 
Shape 
      Oval 
      Taller Than Wide 
 
115 (86%) 
1 (7.5%) 
 
46 (87%) 
0 
 
69 (85%) 
1 (1.2%) 
 
87 (85% 
1 (1%) 
 
28 (88%) 
0 
Texture 
      Solid 
      Mixed Solid/Cystic 
      Cystic 
      Spongiform 
 
77 (57.4%) 
38 (28.4%) 
1 (0.75%) 
1 (0.75%) 
 
32 (60%) 
15 (28%) 
0 
0 
 
45 (56%) 
23 (28%) 
1 (1.2%) 
1 (1.2%) 
 
53 (52%) 
33 (32%) 
1 (1%) 
1 (1%) 
 
24 (75%) 
5 (15%) 
0 
0 
Margins 
(Regular/Irregular) 
      Regular 
      Irregular 
 
 
113 (84%) 
3 (2% 
 
 
46 (87%) 
0 
 
 
67 (83% 
3 (3.7%) 
 
 
86 (84%) 
2 (2%) 
 
 
27 (84% 
1 (3%) 
Margins (Well-
defined/Ill-defined) 
      Well-defined 
      Ill-defined 
 
 
101 (75%) 
15 (11%) 
 
 
40 (75%) 
6 (11%) 
 
 
61 (75%) 
9 (11%) 
 
 
76 (75%) 
12 (12%) 
 
 
25 (78%) 
3 (9%) 
Echogenicity 
      Hyperechoic 
      Isoechoic 
      Hypoechoic 
      Mixed Hyper/Hypo 
      Mixed Iso/Hypo 
 
2 (1.5%) 
2 (1.5% 
47 (35% 
2 (1.5%) 
64 (48%) 
 
1 (1.9%) 
0 
25 (47 %) 
1 (1.9%) 
20 (38%) 
 
1 (1.2%) 
2 (1.2%) 
22 (27%) 
1 (1.2%) 
44 (54%) 
 
1 (1%) 
2 ( 2%) 
37 (36%) 
2 (2%) 
46 (45%) 
 
1 (3%) 
0 
10 (31%) 
0 
18 (56%) 
Halo 
       Y 
       Partial 
       N 
 
26 (19.4%) 
15 (11.2%) 
76 (56.7%) 
 
15 (28%) 
5 (9%) 
27 (51%) 
 
11 (14%) 
10 (12%) 
49 (60%) 
 
19 (19%) 
12 (12%) 
57 (56%) 
 
7 (22%) 
3 (9%) 
19 (59%) 
Calcification 
       Y 
       N 
 
7 (5%) 
110 (82)% 
 
4 (7.5%) 
43 (81%) 
 
3 (3.7%) 
67 (83%) 
 
4 (4%) 
84 (82%) 
 
3 (9%) 
26 (81%) 
Calcification Pattern 
      Annular/Crescent-
like 
      Coarse 
      Rim 
 
2 
 
3 
2 
 
1 
 
2 
1 
 
1 
 
1 
1 
 
1 
 
2 
1 
 
1 
 
1 
1 
Doppler 
      Central 
      Peripheral 
      Both 
      None 
 
1 (0.7%) 
32 (23.9%) 
74 (55.2%) 
4 (3%) 
 
0 
9(17%) 
30 (57%) 
4 (8%) 
 
1 (1.2%) 
23 (28%) 
44 (54%) 
0 
 
1 (1%) 
27 (26%) 
52 (51%) 
2 (2%) 
 
0 
5 (16%) 
22(69%) 
2 (6%) 
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DISCUSSION 
This study did not find any correlation between malignancy risk and age, sex, 
ethnicity, or smoking status. This fits with the findings of other studies that demographics 
are not good predictors of malignancy risk (7). The effect of nodule size on malignancy 
risk is a controversial issue. While some studies have shown size to have an effect on 
prediction of malignancy, most other studies have not (31, 32). Kiernan and Solórzano 
(2017) performed a retrospective study to determine if nodule size was predictive of 
malignancy in Bethesda category III, IV, and V nodules. They found that size alone was 
not predictive of malignancy in nodules that are AUS, FLUS, SFN, or suspicious for 
malignancy, but nodules with Hürthle cell neoplasms were more likely to be malignant if 
larger. Other studies have found nodule size to affect malignancy in nodules greater than 
3cm (31) Another study found that nodules less than 2 cm were more likely to be 
malignant (31) while Wharry et al. (2014) found that malignancy can occur in nodules 
large than 4 cm. They looked at the malignancy rate of nodules with the largest aspect 
greater than 4 cm across all Bethesda categories, and found 29.4% of all indeterminate 
nodules, including Bethesda categories III, IV, and IV, to be malignant (32). The ACR 
TI-RADS system uses nodule size along with its point system to determine how to treat 
thyroid nodules. The more points given to a nodule the smaller the nodule has to be to 
warrant a follow up FNA. We did not find any correlation between nodule size and 
malignancy risk in our study, consistent with the findings of Kiernan and Solórzano 
(2017) that size alone cannot be used to accurately determine malignancy in AUS and 
FLUS nodules. 
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Table 4. Comparison of age, BMI, nodule size and thyroid function tests between 
AUS and FLUS nodules. 
 Mean  total (SD) Mean AUS Mean FLUS p-value 
Age (years) 55.3 (14.1) 54.5 (14.5) 55.9 (14.0) 0.58 
Weight (kg) 84.4 (19.6) 82.2 (17.4) 86.0 (21.0) 0.27 
Height (m) 1.68 (0.09) 1.66 (0.10) 1.69 (0.09) 0.0435 
BMI 29.8 (6.0) 30.1 (5.7) 29.6 (6.2) 0.62 
TSH uIU/ml 1.66 (1.13) 1.81 (1.40) 1.56 (0.90) 0.29 
fT4 (ng/dl) 1.21 (0.89) 1.21 (0.60) 1.21 (1.03) 0.97 
tT3 (ng/dl) 112 (32.5) 106 (42) 114 (31)  
Nodule Size(cm) 2.72 (1.28) 2.69 (1.36) 2.73 (1.22) 0.86 
 
Many studies have investigated the use of sonographic features to predict 
malignancy in indeterminate thyroid nodules. There is a consensus of sonographic 
features that are likely to predict malignancy, but there are no studies that show that a 
particular feature has a high enough PPV for malignancy on its own. A major weakness 
of sonographic predictors is that the sensitivity of a single feature is low. However, 
investigating whether a nodule has a specific number of suspicious features can improve 
the sensitivity. Gao et al. (2017) found that Bethesda category III nodules with 1 
suspicious feature had a sensitivity of 0.75 and specificity of 0.48. As the number of 
suspicious features on ultrasound increased, the nodule was more likely to be malignant. 
Microcalcifications, hypoechogenicity, taller than wide shape, irregular margins, and 
extrathyroidal extension are sonographic features more likely to be malignant (15). 
Norlén et al. (2014) examined the ultrasound features of Bethesda III nodules with 
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regards to malignancy risk. When a nodule had hypoechogenicity, irregular margins, or 
microcalcifications they found it was more likely to be malignant. If all three features 
were there the malignancy risk was 58%, but in the absence of all three features the 
malignancy risk was low at 1.7%.  This malignancy rate of nodules without 
hypoechogenicity, irregular margins, or microcalcifications is similar to the rate of 
incidentally found malignancy in nodules which underwent surgery that were diagnosed 
benign on FNA (33). Other studies have found microcalcifications and irregular margins 
to be predictive of malignancy among indeterminate nodules (34). Extrathyroidal 
extension is a strong indicator of malignancy in PTC (11), however this study did not 
have extrathyroidal extension in any of the 134 nodules. Extrathyroidal extension may be 
a later stage sign of thyroid carcinomas, and not very prevalent in indeterminate thyroid 
nodules. 
Nodules from nodular goiter are diagnosed with atypia because they are prone to 
hemorrhage. Initially this hemorrhage appears nonechogenic on ultrasound, but 
subsequently as coagulation occurs, the nonechogenic region turns into a solid-looking 
hypoechogenic lesion. Since this lesion mostly consists of coagulated blood, it is difficult 
to obtain adequate cellular content, so it is often placed in the atypia category (6).
 
 Calcification has been shown to be a strong indication of malignancy. Topaloglu 
et al. (2016) investigated the risk of malignancy in AUS and FLUS nodules and related 
ultrasonography features. In their study almost 30% of the nodules had calcifications, and 
they found that microcalcifications were more likely to be present in malignant than 
benign AUS and FLUS nodules. Brophy et al. (2016) explored the effect of ultrasound 
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features on malignancy rates in thyroid nodules. They also found that microcalcifications 
and irregular margins are associated with malignancy in indeterminate nodules. They did 
not distinguish between the different indeterminate categories, so their results may differ 
slightly from studies investigating only AUS and FLUS nodules. Özemir et al. (2016) 
investigated the association of papillary thyroid cancer and microcalcifcation in thyroid 
nodules with indeterminate cytology, and showed microcalcification in indeterminate 
nodules increases risk for PTC (35). In their study, 20% of the indeterminate nodules 
were found to have calcification. In the current study, 7 nodules were determined to have 
some form of calcification. It is unknown why there were so few nodules with 
calcifications in the present study when other reports show between 20 and 30% of 
nodules with calcifications. One possible reason may be due to how the ultrasound 
images were read. We used a small number of static images from the original US and not 
the full set of images or real time US, so microcalcifications may have been in the 
nodules, but not in the cross sections we viewed. Three of the 7 nodules were malignant 
upon histopathology. One had the classical variant of PTC, one had the follicular variant 
of PTC, and the third was a well-differentiated PTC. Follicular variants of PTC have been 
shown to have a relatively benign appearance on US and are similar in appearance to a 
follicular neoplasm rather than PTC on US. This held true in this study. The calcified 
nodule that had the follicular variant of PTC had no suspicious features other than the 
calcification while the other malignant calcified nodules were both solid and hypoechoic. 
 There have been multiple studies that looked at subdividing the AUS/FLUS class 
into multiple categories. Baser et al. (2017) looked at the role of TI-RADS in predicting 
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malignancy in the Bethesda category III subcategories of AUS and FLUS. They found 
that TI-RADS was more useful in predicting malignancy in the AUS subcategory, but not 
in the FLUS category. Lee et al. (2016) performed a similar study that compared US 
features of AUS and FLUS nodules, and found that AUS nodules were generally smaller, 
hypoechoic, had noncircumscribed margin, microcalcifications, had taller than wide 
shape, and were more likely to be malignant than the FLUS group. Another study found 
that malignant AUS nodules, but not FLUS, had higher rates of hypoechogenicity, 
noncircumscribed margins, microcalcifications, and nonparallel shape compared to the 
respective benign nodules. Our study also showed that FLUS diagnosed nodules have a 
lower malignancy rate than AUS diagnosed nodules, but no ultrasound features were 
predictive of an AUS nodule or a FLUS nodule. This finding agrees with that of Lee et al. 
(2016) who found that the AUS subcategory indicates a higher malignancy risk than the 
FLUS subcategory (36). Çuhaci et al. (2014) found that the average age was lower in 
malignant nodules than benign nodules in AUS nodules and combined AUS and FLUS 
nodules, but not in FLUS nodules alone (37). The present study did not find the same 
association of increased malignancy risk in younger patients with AUS nodules. 
Gan et al. (2017) subdivided the AUS category into nodules that demonstrated 
nuclear atypia, architectural atypia, and atypical lymphoid cells. They found that nodules 
with nuclear atypia had a significantly higher chance of being malignant than nodules 
without architectural atypia. Baca et al. (2016) subdivided the AUS category into AUS 
with architectural atypia, cytologic atypia, or architectural and nuclear atypia and tested 
the nodules against the Afirma GEC. They found that nodules with architectural atypia 
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were more likely to have benign GEC results than nodules with both architectural and 
cytologic atypia, and there was a trend for nodules with architectural atypia to have a 
higher chance of being benign than nodules with cytologic atypia (38). Nodules 
diagnosed as AUS tend to have nuclear atypia including the presence of nuclear 
pseudoinclusions, grooves, abnormal chromatin pattern, or nuclear overlapping while 
FLUS nodules tend to have architectural atypia like a prominent population of 
microfollicles or Hürthle cell with colloid (36). These studies indicate that it may be 
beneficial to pursue more aggressive options when nodules diagnosed as AUS have 
nuclear or cytologic atypia as opposed to architectural atypia.  
Many studies are directed to study the role of markers like BRAF, RAS, and gene 
expression classifiers in order to assess the risk of malignancy in AUS and FLUS nodules 
(5). While we attempted to evaluate the effect of Afirma GEC, only 30% of nodules had 
an Afirma GEC test performed, and of those, all but one had a suspicious reading. When 
looking at our Afirma GEC suspicious nodules, 80% of them were benign. This suggests 
that the GEC is not an ideal test to diagnose malignancy and a suspicious result would not 
provide significant clinical value. We had a higher number of benign GEC suspicious 
nodules compared to other reports. Other studies have found that the GEC has a PPV of 
35% to 40% (17). However, this is the PPV across all Bethesda categories and not 
Bethesda category III alone. Chaudhary et al. (2016) found a PPV of 38% across 
Bethesda category III and IV, but when taken individually the PPV of category III 
nodules was 15% (21). Another study tested whether nodules that underwent Afirma 
GEC were more likely to show suspicious ultrasound features in indeterminate nodules 
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(39). Of their 21 GEC suspicious nodules, none of them showed suspicious ultrasound 
characteristics. In contrast to their findings, 21 out of our 40 suspicious nodules did not 
show any suspicious features. Villabona et al. (2017) found that after two consecutive 
repeated AUS cytology reports their PPV for GEC suspicious nodules was 91.4%. After a 
single AUS cytology they found the PPV was 66.6%.   
Indeterminate thyroid nodules are often tested for BRAF mutations because they 
are commonly found in papillary thyroid carcinoma. In this study 16 patients were tested 
for BRAF mutations. Of these, 15 were negative and 1 was positive for BRAF mutations. 
Three of the 15 nodules negative for BRAF mutations were malignant upon 
histopathology. Two of these three nodules were identified for the follicular variant of 
papillary carcinoma and the third was identified for the classical variant of thyroid 
carcinoma. Yu et al. (2015) found that the BRAF V600E mutation was found in 61.5% of 
the nodules with PTC in their study. Other studies have found that the prevalence of this 
mutation ranges from 26% to 83% (27). Araujo et al. (2012) found that the BRAF 600E 
mutation was not related to any demographic, clinical, pathological features, or BRAF 
mRNA levels.  
This study did not find any association between BMI and increased risk for 
thyroid nodule malignancy. There are some studies that suggest BMI is a risk factor for 
malignancy while others do not. Wu et al. (2017) found that BMI is associated with 
extrathyroidal invasion and multifocality, advanced TNM staging and tumor size greater 
than 1cm in patients with papillary thyroid cancer. Arduc et al. (2015) found that BMI 
and waist circumference were higher in the malignant group than the benign group (40). 
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Pak et al. (2017) found that BMI is not associated with thyroid nodule malignancy and 
that younger age was a risk factor for malignant incidentalomas. Shin et al. (2016) 
showed that metabolic syndrome is associated with increased rates of thyroid nodules in a 
Korean population (41). 
Sousa et al. (2013) found that there is a positive correlation between thyroid 
volume and insulin resistance. They had TSH, BMI, and leptin as confounding factors, 
and indicated that thyroid volume and insulin resistance were independently correlated. 
They also found that thyroid volume was significantly greater in obese men, but not 
women, than in normal controls. Other studies have shown that causes of thyroid 
dysfunction are associated with insulin resistance in both people with and without 
diabetes mellitus. Further studies looking at the relationship between insulin resistance 
and prevalence of thyroid nodules are needed. 
While we did not see any effect of serum TSH on malignancy of AUS/FLUS 
nodules, other studies have found mixed results. Baser et al. (2016) found that serum 
TSH was higher and fT3 was lower in patients with malignant nodules. They also found a 
general increase of TSH across Bethesda category II through Bethesda category VI 
nodules (42). We may not have found similar results because they included all Bethesda 
categories of thyroid nodules while we only included category III in our study. TSH may 
play a role in cancer development by acting as a growth factor in tumor cells and 
modulating thyroid cell growth and function (42). One reason that TSH is a difficult 
hormone to use to predict thyroid function is because the TSH level of a normal 
individual varies throughout the day (43). The normal range is between 0.3 and 4 uIU/ml. 
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T3 might also play a role in cancer cell growth. The T3 receptor controls the expression 
of thyroid fibroblast growth factor by acting on its promotor (42). In this study, only 1 out 
of 12 nodules where total T3 was evaluated was determined to be malignant, but it was 
within the normal range. Two of the patients with benign nodules had low total T3 levels, 
and no patients had high total T3 levels. We also investigated the free T4 levels. The 
normal range of fT4 is 0.7-2.0 ng/dl and in this study, there were only 3 fT4 values that 
were below the normal range and 4 values that were above the normal range. With few 
fT4 values outside the normal range we were not able to determine if high or low fT4 is 
predictive of malignancy in thyroid nodules. 
This study faced some limitations. First, this study was retrospective and some 
missing data. Secondly, since three different hospital sites were included, there was inter-
observability for FNA diagnoses. However, all ultrasonography images were reviewed by 
a single endocrinologist trained and experienced in performing thyroid US and FNA, so 
there was no inter-rater reliability for the categorization of the ultrasound images. Third, 
we only included patients that had a partial or total thyroidectomy, so by excluding other 
patients with AUS or FLUS nodules there is a possibility of selection bias. This may be 
why we observed a higher malignancy rate that the published data. Many AUS and FLUS 
nodules do not warrant surgery because they may show more benign features on US 
imaging and do not cause compressive symptoms. Finally, this study is limited by small 
sample size. 
In conclusion, this study did not find any demographic or ultrasound features 
predictive of malignancy. However, when a thyroid nodule had at least one suspicious 
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feature consisting of ill-defined margins, irregular margins, hypoechoic echogenicity, 
solid texture, or calcification, there was a trend for the nodule to be malignant. This study 
found that AUS nodules were more likely to be malignant than FLUS nodules. This 
finding held true even when accounting for age, sex, smoking history, and BMI. This is 
likely due to AUS nodules having nuclear atypia whereas FLUS nodules tend to have 
architectural atypia.  
This study found that certain features were predictive of an AUS nodule 
compared to a FLUS nodule. Patients of Hispanic origins were more likely to have AUS 
nodules than FLUS nodules, and nodules with at least 1 suspicious ultrasound feature 
were more likely to be AUS nodules than FLUS nodules. FLUS nodules tend to have a 
more benign appearance than AUS nodules, so FLUS nodules would be expected to have 
fewer suspicious features on ultrasonography than AUS nodules. Taken alone, a single 
feature cannot be predictive of a benign or malignant nodule, or an AUS or FLUS nodule. 
Future studies should investigate suspicious ultrasound features and Afirma or ThyroSeq 
genetic testing as predictors of malignancy in AUS nodules.  
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